Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically proven localized, regional, or metastatic adenocarcinoma of the prostate
• Progressive disease during prior hormonal therapy (both antiandrogen and gonadotropin-releasing hormone) and must continue hormonal therapy
• Measurable tumors or tumor markers
• Bone metastases allowed
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• Karnofsky 60-100%
• Life expectancy:
• At least 3 months
• Hematopoietic:
• WBC at least 3,000/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic:
• No hepatic failure
• Bilirubin no greater than 2.5 mg/dL
• SGOT no greater than 2 times normal
• Renal:
• No chronic renal failure
• BUN less than 60 mg/dL
• Creatinine no greater than 2.5 mg/dL OR
• Creatinine clearance greater than 60 mL/min
• Blood ammonia normal
• Cardiovascular:
• No severe heart disease
• Pulmonary:
• No severe lung disease
• Other:
• Fertile patients must use effective contraception during and for 4 weeks after study participation
• No serious active infections or fever
• No other prior or concurrent second malignancy within the past 2 years
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• At least 4 weeks since prior biologic therapy and recovered
• Chemotherapy:
• At least 4 weeks since prior chemotherapy and recovered
• Endocrine therapy:
• See Disease Characteristics
• Radiotherapy:
• At least 4 weeks since prior radiotherapy and recovered
• Surgery:
• Not specified
• Other:
• At least 4 weeks since prior investigational clinical trial
• No other concurrent treatment for metastatic prostate cancer